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Objective: Depression has been associated with hepatitis C, as well as with its treatment with
proinflammatory cytokines (i.e., interferon). The new direct-acting antiviral agents (DAAs) have
minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins.
We studied the incidence and associated factors of depression in a real-life prospective cohort of
chronic hepatitis C patients treated with the new DAAs.
Methods: The sample was recruited from a cohort of 91 patients with hepatitis C, of both sexes, with
advanced level of fibrosis and no HIV coinfection, consecutively enrolled during a 6-month period for
DAA treatment; those euthymic at baseline (n=54) were selected. All were evaluated through the
depression module of the Patient Health Questionnaire (PHQ-9-DSM-IV), at three time points:
baseline, 4 weeks, and end-of-treatment.
Results: The cumulative incidence (95%CI) of major depression and any depressive disorder during
DAA treatment was 13% (6.4-24.4) and 46.3% (33.7-59.4), respectively. No differences were
observed between those patients with and without cirrhosis or ribavirin treatment (p 4 0.05). Risk
factors for incident major depression during DAA treatment included family depression (relative risk
9.1 [1.62-51.1]), substance use disorder (11.0 [1.7-73.5]), and baseline PHQ-9 score (2.1 [1.1-3.1]).
Conclusions: The findings of this study highlight the importance of screening for new depression
among patients receiving new DAAs, and identify potential associated risk factors.
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Introduction
Depression is a common mental illness1 and a leading
cause of disability worldwide. Chronic exposure to
hepatitis C virus (HCV) and previous antiviral treatment
with interferon alpha has been associated with major
depression.2,3 HCV infection leads to chronic hepatitis C
(CHC) in around 80% of cases, and, if untreated, pro-
gresses to liver cirrhosis in one in five patients within 20
to 50 years after initial infection; of these, 5 to 10% will
develop hepatocellular carcinoma or decompensated liver
disease.4 CHC has been recognized as a systemic
disease with many extrahepatic manifestations, including
feelings of depression, anhedonia, fatigue, irritability,
anxiety, insomnia, and increased sensitivity to pain.5
There is some evidence of direct neuroinvasion by HCV,6
as well as of a chronic, systemic immune activation.7
Interactions of these factors with several neurobiological
pathways, neurotransmission, and neurotrophic mechan-
isms may account for the pathogenesis of neuropsychiatric
symptoms in CHC.8,9
Until a few years ago, antiviral treatment for CHC
involved a weekly injection of pegylated interferon-alpha
(IFNa), a proinflammatory cytokine, together with daily
weight-based doses of ribavirin (RBV) for 24 to 48 weeks.
This regimen was known to cause major depression in
around 30% of patients,3 beside a wide range of other
adverse events (AEs), with a high rate of treatment
discontinuation10 and additional effects on physical and
mental health-related quality of life.11 Increased under-
standing of the HCV viral cycle in the last decade led to
the development of direct-acting antiviral agents (DAA) that
have minimal AEs and high potency, with a direct inhibitory
effect on non-structural viral proteins.12 The sustained
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virological response rate with DAA therapy is over 95% in
most patients. With the use of all-oral DAA combinations,
the short- and long-term prognosis for HCV-infected
patients has improved significantly.13
The aims of this study were to evaluate the incidence
of and risk factors associated with depressive disorders
during DAA treatment in a real-life, prospective cohort of
patients with CHC with advanced liver disease.
Methods
Patients
All consecutive patients with HCV monoinfection starting
all-oral DAA therapy at the Liver Unit of Hospital Clı́nic de
Barcelona (Spain), University of Barcelona, from June to
December 2015 were considered for the study. Patients
with HIV coinfection were not considered for this study,
as they are treated at the Infectious Diseases Unit. From
this initial cohort of patients, we selected those who were
euthymic at baseline to evaluate the incidence of depres-
sion during DAA treatment.
All patients provided written informed consent for parti-
cipation. The study protocol was approved by the institu-
tional research ethics committee.
Demographic, clinical, and virological data at baseline,
were collected. Family and personal history of depression
and alcohol/drug use disorder (SUD) were also recorded.
All participants were clinically assessed at three points:
baseline, at 4 weeks (4W) of DAA therapy, and at the end
of treatment (EOT).
Liver fibrosis was assessed at baseline by means of
transient elastography (TE). Liver stiffness p 7.8 kilo-
pascals (kPa) was defined as F0-1; 7.8-9.4 kPa, as F2;
9.5-13.9 kPa, as F3; and X 14 kPa, as F4 or cirrhosis.
Cirrhosis could also be diagnosed by other methods: liver
biopsy, clinical evidence (i.e., gastroesophageal varices),
and/or the presence of ultrasonographic criteria. Patients
with cirrhosis were screened for hepatocellular carcinoma
every 6 months as per clinical practice.
Antiviral treatment
DAA regimen, duration of therapy (12 or 24 weeks), and
use of concomitant ribavirin (RBV) were planned at the
discretion of the treating physician, in accordance with
national and international recommendations at that time.12
At the time of the study, access to all-oral IFN-free DAA
therapy in Spain was restricted to patients with advanced
liver disease (F3 or cirrhosis) or those with mild liver
disease (F0-2) but concomitant extrahepatic manifesta-
tions. Viral eradication or sustained virological response
(SVR) was defined as undetectable viremia (HCV-RNA)
at 12 weeks after the end of treatment (12AT).
Clinical assessment
All enrolled patients were screened for the presence of
current depressive symptoms by means of the Spanish-
validated version of the self-administered PHQ-9 ques-
tionnaire for CHC patients.14 The items on the PHQ-9
correspond to the symptom criteria for depressive dis-
orders as outlined in the DSM-IV.15 The depression
module (PHQ-9) comprises nine items rated from 0 to
3 (not at all, several days, more than 50% of days, and
nearly every day). Major depression is diagnosed if
patients score 2 or 3 on five or more symptom criteria in
the past 2 weeks, and if one of the symptoms is depres-
sed mood or anhedonia. Other depression is diagnosed
if two, three, or four depressive symptoms have been
present in the last 2 weeks and if one of the symptoms
is depressed mood or anhedonia. This questionnaire
has shown good psychometric properties.14 The PHQ-9
was administered before each medical visit and blinded
to virological results.
Patients with depressive disorders were referred to an
independent senior psychiatrist and treated as necessary.
Statistical analysis
The baseline characteristics of patients in the sample are
presented as mean (standard deviation) for numerical
variables and as absolute and relative frequencies for
categorical variables. The cumulative incidence of major
depression and any depression disorder (i.e., both major
depression and other depressive disorder) during DAA
treatment was estimated and 95% confidence intervals
(95%CI) were calculated. Logistic binomial regression
models were fitted to study possible risk factors for the
incidence of major depression and any depression. An
effect-size measure of these models, relative risk (RR),
was estimated with 95%CIs.
Statistical analyses were carried out using the R free
software environment for statistical computing (The R
Foundation for Statistical Computing; Vienna, Austria),
version 3.4.2. Statistical significance was set at p = 0.05.
Results
Sample selection
During the 6-month study period (June to December
2015), 93 subjects were selected before starting antiviral
therapy, all of whom agreed to participate. One patient
did not start antiviral treatment, and another patient
did not complete the clinical assessment; thus, neither
was included. Of the 91 patients starting DAA treat-
ment, 54 (59.3%) were euthymic at baseline and thus
eligible for inclusion. Table 1 shows their baseline char-
acteristics.
Of the 54 patients who were euthymic at baseline, 46
(85.2%) received DAA treatment (sofosbuvir; ledipasvir;
2D/3D paritaprevir/ombitasvir/ritonavir with or without
dasabuvir; or daclatasvir) for 12 weeks, and 8 (14.8%)
were treated for 24 weeks. Thirty-nine (72%) received
concomitant treatment with RBV. All patients achieved
SVR (100%) after DAA treatment, confirmed at 12AT.
Incidence of depression
Figure 1 shows the cumulative incidence of depression
measured by PHQ-9 during antiviral treatment (at 4 weeks
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and at end-of-treatment) among patients euthymic at
baseline (n=54). The cumulative incidence was 12.9%
(95%CI 6.4-24.4) (n=7) for major depression, and
46.3% (95%CI 33.7-59.4) (n=25) for any depression.
Concerning cirrhosis and use of RBV during DAA treat-
ment, the differences between groups for both major
depression and any depression were not significant
(p 4 0.05).
Risk factors associated with depression during direct-
acting antiviral treatment
Regarding major depression, univariate logistic binomial
regression indicated a statistically significant association
with family history of depression (RR = 9.1, 95%CI 1.6-
51.1), family history of substance use disorder (RR =
11.0, 95%CI 1.7-73.5), and higher PHQ-9 baseline score









Sociodemographic and HCV variables
Age, years 61.1 (12) 60.5 (12.1) 61.3 (12.2) 57.0 (16.2)
Gender (male) 28 (51.9) 13 (46.9) 15 (57.7) 4 (57.1)
HCV genotype
1a 12 (22.2) 6 (20.7) 6 (24) 2 (28.6)
1b 37 (68.5) 22 (75.9) 15 (60) 3 (42.9)
2 1 (1.9) 0 (0) 1 (4) 0 (0)
3 3 (5.6) 1 (3.5) 2 (8) 1 (14.3)
4 1 (1.9) 0 (0) 1 (4) 1 (14.3)
Previous non-responders to PegIFN/RBV
therapy
28 (51.9) 16 (55.2) 14 (56) 1 (14.3)
Liver stiffness X 21 kPa (n=51) 14 ( 27.5) 7 (25.9)w 7 (29.2)y 2 (28.6)||
Fibrosis stage by TE
F0-1 4 (7.4) 2 (6.9) 2 (8) 0 (0)
F2 1 (1.9) 1 (3.5) 0 (0) 0 (0)
F3 11 (20.4) 6 (21.7) 5 (20) 3 (42.9)
F4 38 (70.4) 20 (68.9) 18 (72) 4 (57.1)
Previous decompensation of cirrhosis 10 (26.3) 6 (31.6) 4 (21.1) 1 (25.0)
Child-Pugh Score in cirrhosis (n=37)
A (%) 29 (78.4) 13 (68.4) 16 (88.9) 4 (100)
B (%) 8 (21.6) 6 (31.6) 2 (11.1) 0 (0)
MELD score (n=32)
o 10 20 (62.5) 9 (52.9) 11 (73.3) 3 (100)
X 10 12 (37.5) 8 (47.1) 4 (26.7) 0 (0)
Albumin (g/dL) 41.4 (4.7) 41.0 (4.8) 41.4 (5.0) 44.3 (1.9)
Platelets (109/mL) 127.9 (68.1) 128.9 (63.1) 124.7 (71.2) 147.4 (59.9)
Relevant comorbidityz 54 (100) 29 (100) 25 (100) 7 (100)
Psychiatric variables
Family history of depression 10 (18.5) 6 (21.4) 4 (15.4) 4 (57.1)**
Family history of SUD 6 (11.1) 3 (10.7) 3 (11.5) 3 (42.9)**
Personal history of depression 13 (24.1) 9 (32.1) 4 (15.4) 2 (28.6)
Personal history of SUD 5 (9.3) 3 (10.7) 2 (7.7) 2 (28.6)
PHQ-9 total score (0 to 27) 1.3 (1.4) 1.4 (1.4) 1.2 (1.4) 2.6 (1.4)**
Treatment variables
DAA with RBV 39 (72.2) 20 (71.4) 19 (76.0) 6 (85.7)
DAA without RBV 15 (27.8) 9 (28.6) 6 (24.0) 1 (14.3)
Numerical variables given as mean (SD); categorical variables, as n (%).
DAA = direct-acting antivirals; F = fibrosis score; HCV = hepatitis C virus; IFN = interferon; kPa = kilopascals; MELD = model for end-stage
liver disease; PHQ-9 = Patient Health Questionnaire, depression module; RBV = ribavirin; SD = standard deviation; SUD = substance use
disorder; TE = transient elastography.
*Any depression is the sum of ‘‘other depression’’ (diagnosed if two, three, or four depressive symptoms have been present in the last 2 weeks
and if one of the symptoms is depressed mood or anhedonia) and ‘‘major depression.’’
w ‘‘Major depression’’ is diagnosed if the patient has scored 2 (more than 50% of days) or 3 (nearly every day) on five or more DSM-IV symptom
criteria in the past 2 weeks, and if one of the symptoms is depressed mood or anhedonia.
w n=27; y n=24; || n=7.
z Ischemic cardiovascular events and arrhythmias, current or previous history of neoplastic disease, cryoglobulinemic vasculitis, chronic
obstructive pulmonary disorder (COPD), or any disease potentially impacting activities of daily living.
**p o 0.05.
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(RR = 2.1, 95%CI 1.1-3.9, for every one-point increase
in baseline score). No multivariate models were fitted for
the incidence of depression because of the number of
incident cases throughout the study (n=7/54). Concerning
the development of any depression during DAA, no base-
line characteristic was identified as a risk factor on
univariate analysis.
Discussion
Several important findings were revealed in the present
study. First, 13% of patients who were euthymic at base-
line developed major depression during DAA treatment,
and up to 40% developed depressive symptoms. Dual
antiviral treatment based on IFN-a with RBV was asso-
ciated with a high incidence of major depression (25-
40%) in the past, mainly due to its IFN-a pro-inflamma-
tory properties.3,16 As DAA works instead by direct
inhibition of the various steps of HCV replication, a direct
neuropsychiatric effect was not expected. Thus, other
mechanisms might explain the incidence of depression
observed. First, four in five patients included in our study
received RBV, an antiviral co-agent with an unclear
mechanism of action that is known to have negative effects
on mental health.17 Nevertheless, it was not identified as a
confounding factor when a specific analysis was per-
formed. Second, the incidence of depression may be
related to the advanced liver disease and medical com-
orbidity of this cohort, as these patients often experi-
ence more symptoms related to cirrhosis.18,19 However,
when we controlled for the presence of cirrhosis, no statis-
tically significant differences were found. Importantly, some
factors seem to be associated with a high relative risk of
major depression during DAA treatment.
Second, CHC patients with a family history of depres-
sion before starting antiviral treatment had a more than
fourfold increased risk of developing depression during
DAA treatment. Moreover, every one-point increase in
baseline PHQ-9 score was associated with a twofold risk
(RR = 2.1) of incident depression during DAA treatment.
Neither these factors nor others were associated with the
incidence of mild depressive symptoms during DAA
treatment. In the context of allostatic load, the subgroup
of HCV patients with these risk factors may be more
vulnerable to major depression.20 Large naturalistic cohort
studies would be needed to confirm these results.
This study is not free from limitations. Due to the
sample size, the advanced stage of liver disease in the
patients, their relevant comorbidities, and the absence of
patients with HIV coinfection, any generalization of our
results should be approached with caution. Because of
the naturalistic cohort design, the study lacked a control
group, and patients were included consecutively.
In conclusion, direct-acting antiviral treatment for chro-
nic hepatitis C was associated with a lower incidence of
major depressive episode than previous classical treat-
ment with interferon-alpha. However, the results of this
study highlight the importance of screening for depres-
sion, and its associated risk factors, over the course of
DAA treatment.
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